Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States

Figures & data

Table 1 Patient Characteristics by Treatment Group

Characteristic	Efmoroctocog Alfa	Rurioctocog Alfa Pegol
	n=506	n=268
Age group (as of 2018), n (%)
0 to <6 years	38 (7.5)	10 (3.7)
6 to <12 years	85 (16.8)	29 (10.8)
12 to <18 years	75 (14.8)	45 (16.8)
≥18 years	267 (52.8)	182 (67.9)
Missing	41 (8.1)	2 (0.8)
Hemophilia A severity, n (%)^a
Mild (>5–30%)^b	10 (2.0)	4 (1.5)
Moderate (1–5%)^b	26 (5.1)	15 (5.6)
Severe (<1%)^b	291 (57.5)	214 (79.9)
Unknown	179 (35.4)	35 (13.1)
Top four health care provider states, n (%)^c
California	48 (9.5)	26 (9.7)
Florida	102 (20.2)	23 (8.6)
Massachusetts	23 (4.6)	27 (10.1)
Ohio	41 (8.1)	43 (16.0)

Notes: ^aDisease severity as recorded in the database records. ^bValues in parentheses indicate FVIII levels, percentage of normal. ^cBased on data from all 50 states.

Figure 1 Mean (SD) Weekly Consumption (2015–2018), by age category.

Notes: The n values for both of the “All” columns include records with age missing: 301 missing records for efmoroctocog alfa and seven missing records for rurioctocog alfa pegol.

Abbreviation: n, number of pharmacy dispensing records.